Chronic rhinosinusitis (CRS) is a common disease that affects over 200 million patients worldwide. Sinusitis, as it is often referred to, leads to congestion and facial pain, and reduces the quality of life for the very large affected group. Current treatment options are either ineffective (drugs, nasal sprays) or very invasive (endoscopic operations).
There is a significant unmet need for a home-treatment solution that can effectively alleviate the symptoms of CRS. Bonutti Technologies has developed and patented a hand-held device that uses ultrasound to reduce symptoms and relieve the pain associated with CRS.
The device has been tested in clinical settings, and has proven to significantly reduce discomfort and pain in patients with CRS. NLC has agreed with Bonutti technologies to collaborate in building a venture to commercialize it, bringing this proposition to patients globally.
The device has been tested in a clinical study and has shown to improve pain and discomfort significantly. These clinical results will need to be strengthened further prior to market introduction to ensure sufficient Key Opinion Leader support.
Further next steps include: setting up the supply chain to support global roll-out, developing a (clinical) marketing- and sales strategy, and attracting investors to support the roll-out plan.